SIA
PBMWW

SkyView Investment Advisors’s Psyence Biomedical Warrant PBMWW Stock Holding History

SkyView Investment Advisors’s Portfolio PBMWW Stock Details PBMWW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,500
Closed – – 330
2025
Q4 		$0 Hold
17,500
– – ﹤0.01% 344
2025
Q3 		$0 Hold
17,500
– – ﹤0.01% 341
2025
Q2 		$0 Buy
+17,500
New +$280 ﹤0.01% 339
2024
Q3 		– Sell
-17,500
Closed – – 336
2024
Q2 		$0 Hold
17,500
– – ﹤0.01% 366
2024
Q1 		$1K Buy
+17,500
New +$1.09K ﹤0.01% 326

Other funds holding PBMWW

HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

SkyView Investment Advisors's PBMWW Position: Q1 2026 in Review

SkyView Investment Advisors sold out of Psyence Biomedical Warrant (PBMWW) in Q1 2026, closing a stake of 17,500 shares.

SkyView Investment Advisors first reported a position in PBMWW in Q1 2024 and held it in 5 quarters. The position peaked at $1K in Q1 2024. 19 funds tracked by Wall St. Rank hold PBMWW as of Q1 2026.

  • SkyView Investment Advisors reported no remaining Psyence Biomedical Warrant position as of Q1 2026 after selling out during the quarter.
  • SkyView Investment Advisors sold 17,500 Psyence Biomedical Warrant shares in Q1 2026.
  • SkyView Investment Advisors first reported a position in Psyence Biomedical Warrant in Q1 2024 and held it in 5 quarters.
  • SkyView Investment Advisors's Psyence Biomedical Warrant position peaked at $1K in Q1 2024.
  • 19 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q1 2026.

Based on SkyView Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.